TABLE 5.
Comorbidities of patients with ATL at diagnosis by subtype in a nationwide epidemiological study in Japan, 2010–2011.*
| Total |
ATL subtype |
||||
| Acute | Lymphoma | Chronic | Smoldering | ||
| Total patients, N | 922 | 456 | 237 | 131 | 98 |
| Past medical history | |||||
| Transfusion before 1986, yes, N (%) | 15(1.7) | NA | NA | NA | NA |
| Skin diseases, yes, N (%) | 43 (4.8) | NA | NA | NA | NA |
| Infectious diseases, yes, N (%) | 98 (10.9) | NA | NA | NA | NA |
| Malignancies, N (%) | 108 (12.0) | NA | NA | NA | NA |
| Autoimmune diseases, N (%) | 36 (4.0) | NA | NA | NA | NA |
| Comorbidities at diagnosis | |||||
| Any of diseases, yes, N (% of each subtype) | 297 (32.2) | 145 (32.2) | 67 (28.5) | 43 (33.6) | 42 (43.8) |
| Hematological malignancies, yes, N (% of each subtype) | 8 (0.9) | 4 (0.9) | 2 (0.8) | 0 (0) | 2 (2.0) |
| Non-hematological malignancies, yes, N (% of each subtype) | 113 (12.3) | 53 (11.6) | 21 (8.9) | 17 (13.0) | 22 (22.4) |
| Infectious diseases, yes, N (% of each subtype) | 93 (10.1) | 53 (11.6) | 16 (6.8) | 14 (10.7) | 10 (10.2) |
| Neurologic diseases, yes, N (% of each subtype) | 21 (2.3) | 13 (2.9) | 4 (1.7) | 3 (2.3) | 1 (1.0) |
| Autoimmune diseases, yes, N (% of each subtype) | 9 (1.0) | 3 (0.7) | 1 (0.4) | 3 (2.3) | 2 (2.0) |
*This information was modified from data in Nosaka et al. (2017). ATL = adult T-cell leukemia-lymphoma; IQR = interquartile range; SD = standard deviation; NA = not available.